N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Last updated: May 19, 2025
Sponsor: Memorial Sloan Kettering Cancer Center
Overall Status: Active - Recruiting

Phase

2

Condition

Neuroblastoma

Treatment

Etoposide

Carboplatin

Cytoxan

Clinical Study ID

NCT06528496
24-144
  • Ages 18-19
  • All Genders

Study Summary

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of NB as defined by histopathology, BM metastases plus high urinecatecholamine levels, or positivity in MIBG scan.

  • HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients >18 months old.

  • No more than one prior cycle of HR-NB chemotherapy

  • Age <19 years.

  • Signed informed consent indicating awareness of the investigational nature of thistreatment.

Exclusion

Exclusion Criteria:

  • Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic,pulmonary, hematologic, or gastrointestinal toxicity > grade 2

  • Inability to comply with protocol requirements

  • Pregnancy

Study Design

Total Participants: 45
Treatment Group(s): 11
Primary Treatment: Etoposide
Phase: 2
Study Start date:
July 22, 2024
Estimated Completion Date:
July 22, 2029

Connect with a study center

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10065
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.